OTCMKTS:CPHRF Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis $10.48 +0.03 (+0.29%) As of 02:45 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's Range$10.36▼$10.5350-Day Range$10.06▼$12.8052-Week Range$8.92▼$15.00Volume2,625 shsAverage Volume5,128 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America. In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). These include dry-powder inhalers (DPIs) and metered-dose inhalers (MDIs) that offer patients lower-cost alternatives to branded drugs. In dermatology, the company has brought to market treatments addressing acne, fungal infections of the nails and other skin disorders, often through licensing agreements with innovator companies. Cipher operates primarily in Canada and the United States. Its business model emphasizes strategic partnerships and licensing arrangements, enabling the company to secure exclusive Canadian rights to new products while collaborating with third-party partners for U.S. commercialization. This approach allows Cipher to leverage established regulatory approvals and focus resources on market access, sales and marketing. Looking ahead, Cipher continues to expand its product pipeline through in-licensing and development of both generic and branded prescription drugs. The company is advancing new formulations in respiratory care and exploring additional dermatology assets, aiming to build a diversified specialty pharmaceutical portfolio that delivers growth through product launches and ongoing royalty streams.AI Generated. May Contain Errors. Read More Receive CPHRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPHRF Stock News HeadlinesCipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration AwardSeptember 1, 2026 | finance.yahoo.comCipher Pharmaceuticals Balances U.S. Strain With Epuris StrengthAugust 25, 2026 | theglobeandmail.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 16 at 1:00 AM | Golden Portfolio (Ad)Cipher Pharmaceuticals Inc (CPHRF) (Q2 2026) Earnings Call Highlights: Epuris Growth and ...August 12, 2026 | finance.yahoo.comCipher Pharmaceuticals Inc CPHRFAugust 4, 2026 | morningstar.comMCipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®July 6, 2026 | finance.yahoo.comCaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)April 7, 2026 | businesswire.comCipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 13, 2026 | finance.yahoo.comSee More Headlines CPHRF Stock Analysis - Frequently Asked Questions How have CPHRF shares performed this year? Cipher Pharmaceuticals' stock was trading at $10.98 at the beginning of 2026. Since then, CPHRF stock has decreased by 4.6% and is now trading at $10.48. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The firm earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/05/2016Today9/16/2026Next Earnings (Estimated)11/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CIKN/A Webwww.cipherpharma.com Phone(905) 602-5840FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:CPHRF) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.